rs28897681
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP6_Very_Strong
The NM_007294.4(BRCA1):c.2083G>T(p.Asp695Tyr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000378 in 1,613,910 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Benign (★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D695N) has been classified as Likely benign.
Frequency
Consequence
NM_007294.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152164Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000438 AC: 11AN: 251166Hom.: 0 AF XY: 0.0000442 AC XY: 6AN XY: 135732
GnomAD4 exome AF: 0.0000404 AC: 59AN: 1461746Hom.: 0 Cov.: 42 AF XY: 0.0000468 AC XY: 34AN XY: 727174
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152164Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74338
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:1Benign:4
- -
IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 0.000263 -
- -
- -
- -
not specified Benign:3
- -
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Variant summary: BRCA1 c.2083G>T (p.Asp695Tyr) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.7e-05 in 276880 control chromosomes (gnomAD). This frequency is not significantly higher than expected for a pathogenic variant in BRCA1 causing Hereditary Breast and Ovarian Cancer (4.7e-05 vs 1.00e-03), allowing no conclusion about variant significance. This variant, c.2083G>T, has been reported in the literature in individuals affected with Hereditary Breast and Ovarian Cancer (Lu_2012, Anczukow_2008). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. Co-occurrences with other pathogenic variant(s) have been reported (BRCA1: c.5266dup (p.Gln1756ProfsX74) and c.3760A (p.Lys1254X); BRCA2: c.145G>T (p.Glu49X), c.5350_5351delAA (p.Asn1784HisfsX2), and c.1800T>G (p.Tyr600X)), providing supporting evidence for a benign role. The following publications have been ascertained in the context of this evaluation (PMID: 16518693, 22476429, 18273839). Nine submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as likely benign. -
Hereditary cancer-predisposing syndrome Benign:3
- -
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
NICE approved PARP inhibitor treatment Benign:1
BS3_Strong,BP1,BP5_Very Strong -
not provided Benign:1
- -
Malignant tumor of breast Benign:1
The BRCA1 p.Asp695Tyr variant was identified in dbSNP (ID: rs28897681), LOVD, BIC (2X with unknown clinical importance), and UMD (19X as an unclassified variant). In the UMD database, this variant was identified in two samples with a second pathogenic BRCA2 or BRCA1 mutation (BRCA 1 c.3760A>T (p.Lys1254X) and BRCA2 c.5350 5351delAA (p.Asn1784HisfsX2)), increasing the likelihood that this variant does not have clinical significance. The variant was listed in the NHLBI Exome Sequencing project; however it was identified in only one out of 8600 tested European American chromosomes (frequency: 0.0001). The p.Asp695 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. Three studies predict the variant to affect protein function or confer high risk; however, these predictions are based solely on evolutionary conservation analyses (Burk-Herrick 2006, Fleming 2003, Ramirez 2004). In the HGMD and BIC databases, another variant (c.2083G>A, p.D695N) was also listed with unknown clinical significance, and Greenman (1998) suggests that it may be a polymorphism. In summary, the clinical significance of this variant cannot be determined with certainty at this time, although we would lean towards a more benign role for this variant. This variant is classified as predicted benign. -
Hereditary breast ovarian cancer syndrome Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at